Search Results
Your search for 3 matches 15342 pages
Showing 14851 - 14900Accelerated Methotrexate, Vinblastine, Doxorubicin, Cisplatin With Pegfilgrastim Is Effective, Well-Tolerated Neoadjuvant Therapy for Bladder Cancer
Although neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer, it is not widely used due to concerns over toxicity and delayed cystectomy. In a phase II trial reported in the Journal of Clinical Oncology, Plimack et al evaluated whether a neoadjuvant...
Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin With Pegfilgrastim: Safe and Effective in Muscle-Invasive Urothelial Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Choueiri et al found that a neoadjuvant four-cycle/8-week regimen of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin was well tolerated and effective in patients with muscle-invasive urothelial cancer. Study Details ...
Carcinogens Found in Water Pipe Smoking May Increase Risk for Cancer
Researchers investigating the effects of water pipe smoking on the health of young adults have found elevated levels of nicotine, cotinine, tobacco-related cancer-causing agents, and volatile organic compounds, including benzene and acrolein, in the urine of users. Given the significant intake of...
Necitumumab Plus Chemotherapy Shows Overall Survival Benefit in Patients With Squamous NSCLC
In the large phase III SQUIRE trial of necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin in the first-line treatment of advanced squamous non–small cell lung cancer (NSCLC), patients with stage IV metastatic disease showed a statistically significant improvement in overall...
Delaying Androgen Deprivation Therapy May Be Safe for Men With Prostate Cancer Relapse Detected by PSA Testing
According to a large, population-based observational study of men who had a prostate-specific antigen (PSA)-only based relapse after prostate surgery or radiation therapy, delaying androgen deprivation therapy until the onset of symptoms or appearance of cancer on a scan does not substantially...
Diffuse Erythema Predicts Complete Remission of Skin Disease With Alemtuzumab in Leukemic Cutaneous T-Cell Lymphoma
As reported in a research letter in JAMA Dermatology, Watanabe et al found that diffuse erythema at presentation in patients with leukemic T-cell lymphoma was associated with better response to low-dose alemtuzumab (Campath) compared with patients presenting with preexisting plaques or tumors....
Phase II Feasibility Study Tests Four Molecular-Based Hypotheses in Advanced Colorectal Cancer
In a phase II feasibility study (MRC FOCUS3) reported in British Journal of Cancer, Maughan et al used KRAS and BRAF mutation status and topoisomerase-1 expression status to randomly assign patients with advanced colorectal cancer to molecular hypothesis–driven treatment or control treatment. ...
Squamous Cell Carcinoma Within Advanced Basal Cell Carcinoma During Vismodegib Treatment: Importance of Serial Biopsy
In a report in JAMA Dermatology, Zhu et al discuss two cases in which clinically significant squamous cell carcinoma was found within the tumor bed of locally advanced basal cell carcinoma during vismodegib (Erivedge) treatment for basal cell carcinoma. In one, basal cell carcinoma tumor shrinkage...
Tools for Identifying Pathologically Insignificant Prostate Cancer Are Inaccurate In Unscreened Men
In a study reported in British Journal of Cancer, Shaw et al assessed the accuracy of several reported criteria for identifying insignificant prostate cancer for active surveillance in a population of unscreened men. None of the examined tools provided sufficient discrimination of insignificant...
Phase I Study Finds Novel Antibody Shows Promise in Children With Advanced Neuroblastoma
Researchers from St. Jude Children’s Research Hospital conducted a phase I study of hu14.18K322A, an experimental monoclonal antibody genetically engineered at the hospital, in 38 children with refractory or recurrent neuroblastoma. The patients received escalating doses of hu14.18K322A...
Tumor Factors Associated With Poorer Overall Survival in Patients With Intrahepatic Cholangiocarcinoma Undergoing Curative Intent Surgery
There are limited data on outcomes after surgery for intrahepatic cholangiocarcinoma. In a systematic review and meta-analysis reported in JAMA Surgery, Mavros et al found that tumor characteristics are the primary predictors of survival after curative intent surgery, indicating the need for...
Magnetic Resonance–Guided Focused Ultrasound Reduces Pain From Bone Metastases
Few options are available to treat pain from bone metastases in patients refractory to drug and radiation therapy. In a phase III study reported in the Journal of the National Cancer Institute, Hurwitz et al found significant pain relief using magnetic resonance–guided focused ultrasound...
Adding Neoadjuvant Carboplatin to Taxane, Anthracycline, and Targeted Therapy Increases Pathologic Complete Response in Triple-Negative Breast Cancer
Preclinical data suggest that triple-negative breast cancer is sensitive to interstrand crosslinking agents and that the combination of a taxane, trastuzumab (Herceptin), and a platinum may have synergistic effects in HER2-positive breast cancer. In a randomized phase II trial (GeparSixto, German...
Glutamine Ratio Is Key Indicator of Tumor Aggression in Ovarian Cancer, Study Finds
An analysis of the metabolic profiles of hundreds of ovarian tumors has revealed a new test to determine whether ovarian cancer cells have the potential to metastasize. The study, which was published in Molecular Systems Biology, also suggests how ovarian cancer treatments can be tailored based on...
Good Prognosis for High-Risk Ph-Negative ALL With Chemotherapy After Early Cytologic Response and Low Minimal Residual Disease Level on Flow Cytometry
In a Spanish trial (PETHEMA ALL-AR-03) reported in the Journal of Clinical Oncology, Ribera et al found high disease-free and overall survival rates with delayed consolidation and maintenance chemotherapy in high-risk Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL)...
Ado-Trastuzumab Emtansine Improves Progression-Free Survival vs Physician’s Choice in Previously Treated Advanced HER2-Positive Breast Cancer
There are few treatment options for breast cancer patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic disease. In the open-label phase III TH3RESA trial reported in The Lancet Oncology by Krop and et al, ado-trastuzumab emtansine (Kadcyla)...
ASCO Releases Companion Guideline on Disease Management for Patients With Advanced HER2-Positive Breast Cancer and Brain Metastases
As many as half of patients with metastatic HER2-positive breast cancer develop brain metastases over time. The American Society of Clinical Oncology recently released a clinical practice guideline on disease management for patients with advanced HER2-positive breast cancer and brain metastases. A...
Modafinil Not Better Than Placebo for Fatigue in Lung Cancer Patients
In a trial reported in the Journal of Clinical Oncology, Spathis et al found that that the central nervous system (CNS) stimulant modafinil had no effect on fatigue compared with placebo in patients with advanced non–small cell lung cancer (NSCLC). Fatigue improved in both groups during the...
Increased Incidence of Thyroid Cancer: An Epidemic of Diagnosis?
In a study reported in JAMA Otolaryngology Head & Neck Surgery, Davies and Gilbert found that the incidence of thyroid cancer has nearly tripled since 1975. However, the increase appears to represent an “epidemic of diagnosis” and to almost exclusively represent increased diagnosis...
Hyperfractionated Radiation Therapy Improves Local-Regional Control Without Increasing Late Toxicity in Locally Advanced Head and Neck Cancer
Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy experienced improved local-regional control and, with patients censored at 5 years, improved overall survival with no increase in late toxicity, according to a study...
Anti–Interleukin-1 Alpha Antibody MABp1 Is Well Tolerated, Safe, and Active in Phase I Trial in Refractory Cancers
Expression of the inflammatory cytokine interleukin (IL)-1 alpha is a very early step in the inflammatory response that characterizes the malignant phenotype and that is associated with angiogenesis, tumor invasiveness, metastasis, and cachexia. In a phase I dose-escalation study reported in The...
Irradiated Stents Prolong Survival and Reduce Dysphagia Compared With Conventional Stents as Palliative Treatment in Unresectable Esophageal Cancer
In a single-blind phase III trial reported in The Lancet Oncology, Zhu et al compared the use of 125iodine seed–loaded vs conventional covered stents along with single high-dose brachytherapy as palliative treatment in patients with unresectable esophageal cancer. Use of the irradiated stents ...
Poor Quality of Life Does Not Predict Low Survival Rates in High-Risk Lung Cancer Patients Undergoing Surgery
Quality of life is rarely reported in surgical publications, yet it can be an important metric that can be of use to physicians and patients when making treatment decisions. Prior studies of average-risk patients undergoing lobectomy suggested that low baseline quality-of-life scores predict worse...
No Difference in Disease-Free Survival but Less Steroid Dependence With Adrenal-Sparing Surgery vs Adrenalectomy in Pheochromocytoma
Molecular diagnosis and preventive surgery have been successful in preventing medullary thyroid cancer in patients with multiple endocrine neoplasia type 2 syndrome. In a retrospective population-based study reported in The Lancet Oncology, Castinetti et al found no difference in disease-free...
Sorafenib Improves Progression-Free Survival in Progressive Radioactive Iodine–Refractory Differentiated Thyroid Cancer
Patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer have a poor prognosis. In the double-blind phase III DECISION trial reported in The Lancet, Brose et al found that sorafenib (Nexavar) increased progression-free survival in this setting. The...
Tumor Regression Grading After Preoperative Chemoradiotherapy for Rectal Carcinoma Predicts Distant Metastasis Risk and Disease-Free Survival
In a study reported in the Journal of Clinical Oncology, Fokas et al found that prospectively evaluated tumor regression grading was a significant prognostic factor for distant metastasis and disease-free survival after 132 months of follow-up in patients with locally advanced rectal carcinoma...
ASTRO Issues Guideline on the Role of Postoperative Radiation Therapy for Endometrial Cancer
The American Society for Radiation Oncology (ASTRO) has issued a new guideline, “The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline,” that details the use of adjuvant radiation therapy in the treatment of endometrial cancer. The...
FDA Approves First HPV Test for Primary Cervical Cancer Screening
The U.S. Food and Drug Administration (FDA) today approved the first human papillomavirus (HPV) DNA test that can be used as a primary cervical cancer screening test for women aged 25 years and older. The test also can provide information about the patient’s risk for developing cervical...
Ado-Trastuzumab Emtansine Plus Pertuzumab Shows Activity and No Unexpected Toxicity in HER2-Positive Locally Advanced or Metastatic Breast Cancer
In a phase IIa trial reported in the Journal of Clinical Oncology, Miller et al assessed combined HER2-targeted therapy with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) and pertuzumab (Perjeta) in women with HER2-positive locally advanced or metastatic breast cancer. Pertuzumab...
FDA Approves Siltuximab for Rare Castleman’s Disease
The U.S. Food and Drug Administration (FDA) today approved siltuximab (Sylvant injection) for the treatment of patients with multicentric Castleman’s disease who are human immunodeficiency virus (HIV)-negative and human herpes virus-8 (HHV-8)-negative. Multicentric Castleman’s...
Adding Everolimus to Trastuzumab/Vinorelbine Prolongs Progression-Free Survival but Increases Toxicity in Trastuzumab-Resistant Advanced Breast Cancer
Disease progression in HER2-positive breast cancer treated with trastuzumab (Herceptin) may be associated with PI3K/Akt/mTOR pathway activation, and use of an mTOR inhibitor might restore trastuzumab sensitivity. In the double-blind phase III BOLERO-3 trial reported in The Lancet Oncology,...
FDA Approves Ramucirumab for Stomach Cancer
The U.S. Food and Drug Administration (FDA) has approved ramucirumab (Cyramza) to treat patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy....
Interim Analysis of Phase III AVAST-M Trial Shows No Overall Survival Benefit of Adjuvant Bevacizumab vs Observation in High-Risk Melanoma
Bevacizumab has exhibited limited activity in advanced melanoma. In an interim analysis of the open-label phase III AVAST-M trial reported in The Lancet Oncology, Corrie et al found that adjuvant bevacizumab (Avastin) in patients with resected melanoma at high risk of recurrence has thus far...
Gene Signatures Identified by Meta-Analysis Predict Survival and Suboptimal Debulking in Late-Stage Ovarian Cancer
As reported in the Journal of the National Cancer Institute, Riester et al have identified gene-expression signatures predictive of survival and debulking status in late-stage ovarian cancer. Study Details The study involved meta-analytic techniques using integrated data from 13 publicly...
European Phase II Study Indicates Activity of Enzalutamide in Hormone-Naive Prostate Cancer
As reported in The Lancet Oncology by Tombal et al, a single-arm phase II trial of the androgen receptor inhibitor enzalutamide (Xtandi) has shown that the agent is active in suppressing disease and well tolerated in men with hormone-naive prostate cancer. In this ongoing trial, 67 men with...
Chronic Inflammation in Benign Prostate Tissue Is Associated With Aggressive Prostate Cancer
An analysis of prostate tissue biopsies collected from participants in the placebo arm of the Prostate Cancer Prevention Trial (PCPT) has found that those whose benign prostate tissue had chronic inflammation had 1.78 times higher odds of having prostate cancer, and 2.24 times higher odds of having ...
FDA Approves Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) today approved ofatumumab (Arzerra) injection in combination with chlorambucil (Leukeran) for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate. Trial...
Total Parotidectomy May Benefit Patients With Cutaneous Squamous Cell Carcinoma or Malignant Melanoma With Metastasis to the Parotid Superficial Lobe
The optimal extent of surgical resection is unclear in patients with parotid superficial lobe lymph node metastasis from cutaneous squamous cell carcinoma and malignant melanoma. In a single-institution retrospective review reported in JAMA Otolaryngology Head & Neck Surgery, Thom et al found...
Panitumumab Not Inferior to Cetuximab in Overall Survival in Chemotherapy-Refractory Wild-Type KRAS Metastatic Colorectal Cancer
In the open-label noninferiority phase III ASPECCT trial reported in The Lancet Oncology, Price et al found that anti-EGFR monoclonal antibody treatment with panitumumab (Vectibix) produced a noninferior overall survival outcome vs cetuximab (Erbitux) in patients with chemotherapy-refractory...
Novel Prognostic Indices Validated for Cytogenetically Normal Acute Myeloid Leukemia
Cytogenetically normal acute myeloid leukemia (AML) is the largest and most heterogeneous cytogenetic AML subgroup. As reported in the Journal of Clinical Oncology, Pastore et al have developed a widely applicable prognostic model for cytogenetically normal AML that combines established patient and ...
Investigators Attempt to Increase Lapatinib Exposure Through Intermittent Dosing in HER2-Positive Breast Cancer
HER3 links with HER2 in a reciprocal relationship including negative feedback signaling that can upregulate HER2-HER3 signaling to compensate for HER2 inhibition. This signal-buffering capacity protects HER2-HER3 against a nearly 2-log inhibition of HER2 catalytic activity. The anti-HER2 tyrosine...
Quality-of-Life Study in NCIC MAP.3 Trial Shows Limited Negative Impact of Daily Exemestane in Breast Cancer Prevention
The National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary Prevention 3) trial showed that daily exemestane treatment reduced invasive breast cancer risk by 65% among postmenopausal women. In a quality-of-life study in the MAP.3 population reported in the Journal of...
Study Finds a Quarter of Men Drop Out of Prostate Cancer Monitoring, Casting Doubt on Safety of Active Surveillance
Noncompliance appears to be a major challenge for active surveillance, according to the results of long-term follow-up of patients with prostate cancer presented at the European Association of Urology 29th Annual Congress in Stockholm. Over a quarter of men dropped out of the active surveillance...
ASCO Issues Adapted Guideline on Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer
ASCO has adapted the Pan-Canadian Practice Guideline on Screening, Assessment, and Care of Psychosocial Distress (Depression, Anxiety) in Adults With Cancer for use in the screening, assessment, and care of anxiety and depressive symptoms in adults with cancer. The adapted guideline, reported in...
ASCO Releases Guideline on Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers
The American Society of Clinical Oncology has released a clinical practice guideline on prevention and treatment of chemotherapy-induced peripheral neuropathy in adult cancer patients, published in the Journal of Clinical Oncology. The overall incidence of chemotherapy-induced peripheral neuropathy ...
Gene Sequencing Project Discovers Mutations Tied to High-Grade Gliomas in Young Children
The St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric high-grade gliomas. The findings by Wu et al were published in Nature Genetics and may lead to improved outcomes for children with these brain...
Worse Progression-Free Survival With Addition of Cetuximab to Chemotherapy in Patients With Resectable Colorectal Liver Metastasis
Surgery for liver metastasis from colorectal cancer is associated with overall survival of approximately 40% at 5 years, and progression-free survival is increased with the addition of oxaliplatin and fluorouracil (5-FU). The addition of cetuximab (Erbitux) to chemotherapy has produced a survival...
Older People With Faster Decline in Memory and Thinking Skills May Have Lower Risk of Cancer Death
Older people who are starting to have memory and thinking problems, but do not yet have dementia, may have a lower risk of dying from cancer than people who have no memory and thinking problems, according to a study by Benito-León et al published online in Neurology. “Studies have...
Long-Term Hormone Therapy Is Associated With Improved Survival in Women With Non‒Small Cell Lung Cancer
In women with non–small cell lung cancer, long-term hormone therapy, particularly estrogen plus progesterone, is associated with improved survival, according to the results of a retrospective study presented by Katcoff et al in the Journal of Thoracic Oncology. This finding may lead to...
Phase II Study Suggests Promise of Intermittent Chemotherapy Plus Continuous Cetuximab in Advanced KRAS Wild-Type Colorectal Cancer
In a phase II study (COIN-B) reported in The Lancet Oncology, Wasan et al examined the addition of continuous or intermittent cetuximab (Erbitux) to intermittent chemotherapy in previously untreated advanced KRAS wild-type colorectal cancer. Continuous cetuximab appeared to be associated with...
